Immune Globulin Intramuscular Injection (GamaSTAN)

GamaSTAN IM is covered only as a single‑dose (30‑day) intramuscular injection for FDA‑approved post‑exposure uses (hepatitis A if given within 2 weeks, measles in susceptible persons exposed <6 days, varicella only when VZIG is unavailable, rubella in exposed pregnant women who will not consider termination) and an off‑label compendial use for hepatitis A pre‑exposure prophylaxis when vaccine is unavailable, contraindicated, or for travel; it is not indicated for persons with clinical hepatitis A or exposures beyond the specified windows. Approval requires documentation of the indication/timing and that vaccine/VZIG is unavailable or contraindicated where applicable, plus safety criteria (in IgA‑deficient patients no anti‑IgA antibodies and no history of hypersensitivity, no severe thrombocytopenia, no coagulation disorders) and IM dosing justification.

"For prophylaxis following exposure to hepatitis A. The prophylactic value of GamaSTAN is greatest when given before or soon after exposure to hepatitis A."